[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 17, 1997

Bioequivalence of Levothyroxine Preparations: Issues of Science, Publication, and Advertising

Author Affiliations

University of California, San Francisco, School of Medicine

JAMA. 1997;278(11):897-898. doi:10.1001/jama.1997.03550110035025

To the Editor.  —It is bad enough that medical journals accept advertisements from pharmaceutical companies, as advertisements should fundamentally play no role in clinical decision making. It is worse when an issue of a journal that contains an article evaluating the efficacy and safety of a specific drug also includes advertisements from manufacturers of the drug in question.The Editorial by Dr Rennie1 confronts the shameful with-holding of an article2 on the bioequivalence of various levothyroxine preparations by the legal bullying of a manufacturer that stood to lose millions by its publication. How galling is it then that the same issue which—correctly, albeit rather sanctimoniously—demonstrates the insidiousness of conflicts arising from partnerships between science and industry also contains 2 advertisements3 from another levothyroxine manufacturer that stands to gain in market share as a result of the article by Dong et al and the well-earned criticism of Knoll Pharmaceutical Company